At #ObesityWeek, people are speculating about innovations HCPs in general practice can embrace . We’re getting a good look at two candidates to be the #GPGLP1.

Orforglipron and oral semaglutide from @elilillyandcompany.bsky.social and @novonordisk.bsky.social.
conscienhealth.org/2025/11/ow20...